Kobayashi Pharmaceutical Co., Ltd.Kobayashi Pharmaceutical Co., Ltd.Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.67 B‬USD
0.31USD
‪23.33 M‬USD
‪1.06 B‬USD
‪44.49 M‬
Beta (1Y)
0.38

About Kobayashi Pharmaceutical Co., Ltd.


CEO
Norikaz Toyoda
Headquarters
Osaka
Founded
1919
IPO date
Apr 20, 1999
Identifiers
2
ISIN JP3301100008
Kobayashi Pharmaceutical Co., Ltd. engages in the manufacture and sale of over-the-counter (OTC) pharmaceuticals, quasi-drugs, air fresheners, and sanitary products. It operates through the following segments: Domestic Business and International Business. The Domestic Business segment manufactures and sells health care products, daily necessities, skin care products, and body warmers in Japan. The International Business segment sells beauty and health care products overseas. . The company was founded by Chubei Kobayashi in February 1886 and is headquartered in Osaka, Japan.

Check out other big names from the same industry as KBYPF.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
1306
Nomura Asset NEXT FUNDS TOPIX ETF (1306)
Weight
0.03%
Market value
‪56.02 M‬
USD
1308
Nikko Asset Listed Index TOPIX ETF (1308)
Weight
0.03%
Market value
‪26.83 M‬
USD
1305
iFreeETF TOPIX (Yearly Dividend Type)
Weight
0.03%
Market value
‪24.18 M‬
USD
1348
MAXIS TOPIX ETF
Weight
0.03%
Market value
‪8.06 M‬
USD
SCZ
iShares MSCI EAFE Small-Cap ETF
Weight
0.05%
Market value
‪6.36 M‬
USD
1475
iShares Core TOPIX ETF
Weight
0.03%
Market value
‪4.73 M‬
USD
VIGI
Vanguard International Dividend Appreciation ETF
Weight
0.04%
Market value
‪3.55 M‬
USD
1593
MAXIS JPX-Nikkei Index 400 ETF
Weight
0.04%
Market value
‪2.80 M‬
USD
IJPA
iShares Core MSCI Japan IMI UCITS ETF
Weight
0.03%
Market value
‪2.14 M‬
USD
0A3F
iShares Core MSCI Japan IMI UCITS ETF
Weight
0.03%
Market value
‪2.14 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of KBYPF is 34.05 USD — it has decreased by −2.71% in the past 24 hours. Watch Kobayashi Pharmaceutical Co., Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Kobayashi Pharmaceutical Co., Ltd. stocks are traded under the ticker KBYPF.
We've gathered analysts' opinions on Kobayashi Pharmaceutical Co., Ltd. future price: according to them, KBYPF price has a max estimate of 43.70 USD and a min estimate of 31.96 USD. Watch KBYPF chart and read a more detailed Kobayashi Pharmaceutical Co., Ltd. stock forecast: see what analysts think of Kobayashi Pharmaceutical Co., Ltd. and suggest that you do with its stocks.
KBYPF reached its all-time high on Jul 14, 2021 with the price of 85.30 USD, and its all-time low was 32.49 USD and was reached on Mar 27, 2024. View more price dynamics on KBYPF chart.
See other stocks reaching their highest and lowest prices.
KBYPF stock is 2.79% volatile and has beta coefficient of 0.38. Track Kobayashi Pharmaceutical Co., Ltd. stock price on the chart and check out the list of the most volatile stocks — is Kobayashi Pharmaceutical Co., Ltd. there?
Today Kobayashi Pharmaceutical Co., Ltd. has the market capitalization of ‪2.67 B‬, it has decreased by −0.53% over the last week.
Yes, you can track Kobayashi Pharmaceutical Co., Ltd. financials in yearly and quarterly reports right on TradingView.
Kobayashi Pharmaceutical Co., Ltd. is going to release the next earnings report on May 8, 2026. Keep track of upcoming events with our Earnings Calendar.
Kobayashi Pharmaceutical Co., Ltd. revenue for the last quarter amounts to ‪342.69 M‬ USD, despite the estimated figure of ‪340.59 M‬ USD. In the next quarter, revenue is expected to reach ‪215.99 M‬ USD.
KBYPF net income for the last quarter is ‪−20.12 M‬ USD, while the quarter before that showed ‪24.63 M‬ USD of net income which accounts for −181.70% change. Track more Kobayashi Pharmaceutical Co., Ltd. financial stats to get the full picture.
Kobayashi Pharmaceutical Co., Ltd. dividend yield was 1.92% in 2025, and payout ratio reached 211.46%. The year before the numbers were 1.64% and 75.32% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kobayashi Pharmaceutical Co., Ltd. EBITDA is ‪159.10 M‬ USD, and current EBITDA margin is 14.23%. See more stats in Kobayashi Pharmaceutical Co., Ltd. financial statements.
Like other stocks, KBYPF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kobayashi Pharmaceutical Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kobayashi Pharmaceutical Co., Ltd. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kobayashi Pharmaceutical Co., Ltd. stock shows the neutral signal. See more of Kobayashi Pharmaceutical Co., Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.